Evidence map›Paper›PMID 31601688›Full record

ArticleHaematologica2020

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma.

Paolo Strati, Mohamed Amin Ahmed, Nathan H Fowler, Loretta J Nastoupil, Felipe Samaniego, Luis E Fayad, Fredrick B Hagemeister, Jorge E Romaguera, Alma Rodriguez, Michael Wang and 6 more

Abstract read
In one paragraph

Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Article
  8. Observational
  9. Review
  10. Review
  11. The Predictive Role of BaselineDiagnostics (Basel, Switzerland) · 2025
    Article
  12. Article
  13. Article
  14. The POD24 challenge: where do we go from here for early progressors?Hematology. American Society of Hematology. Education Program · 2024
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Paolo StratiDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Mohamed Amin AhmedDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Nathan H FowlerDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Loretta J NastoupilDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Felipe SamaniegoDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Luis E FayadDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Fredrick B HagemeisterDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Jorge E RomagueraDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Alma RodriguezDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Michael WangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Jason R WestinDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Chan CheahDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Mansoor NooraniDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Lei FengDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Richard E DavisDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Sattva S NeelapuDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center sneelapu@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

The impact of pre-treatment maximum standardized uptake value (SUV

Indexed as

Fluorodeoxyglucose F18Lymphoma, FollicularHumansLymph NodesPositron-Emission TomographyPrognosisRetrospective StudiesFluorodeoxyglucose F18

Identifiers

PMID31601688
PMCPMC7327641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.